← Back to Patent Explorer
US4229478A Expired / Lapsed US ⏱️ 0.0 years remaining

Naphthaquinone anti-psoriatic agents

Assignee: Syntex USA LLC
•
Filing: 1978-06-05
•
Granted: 1980-10-21
•
Expires: 1998-06-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Psoriasis in mammals is relieved by topically administering substituted naphthaquinones of the formula: <IMAGE> (I) where R1 and R2 are the same or different and are hydrogen, hydroxy, alkoxy or acylamino and R3 is hydrogen, halo, cyano or alkoxy with the proviso that R1 and R2 are not both hydrogen.

Inventors

  • 👤 Gordon H. Jones
  • 👤 John Young

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 14:08
CPC Classifications
C; C07; C07C; C07C50/00; C07C50/26; C07C50/32; A; A61; A61P; A61P17/00; C07C17/00; C07C17/093; C07C17/10; C07C17/14; C07C45/00; C07C45/51; C07C45/54; C07C46/00

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 103 words
A method for relieving the condition of psoriasis which comprises topically administering to mammals in need thereof an amount of a compound of the formula ##STR10## where R 1 and R 2 are the same or different and are hydrogen, hydroxy or C 1 to C 18 linear or branched alkoxy and R 3 is hydrogen, halo, cyano or C 1 to C 18 linear or branched alkoxy, with the proviso that R 1 and R 2 are not both hydrogen, sufficient to relieve the condition of psoriasis in mammals in combination with a pharmaceutically acceptable, non-toxic carrier suitable for said administration form.
Claim 2
Independent Claim 103 words
A method for relieving the condition of psoriasis which comprises topically administering to mammals in need thereof an amount of a compound of the formula ##STR10## where R 1 and R 2 are the same or different and are hydrogen, hydroxy or C 1 to C 18 linear or branched alkoxy and R 3 is hydrogen, halo, cyano or C 1 to C 18 linear or branched alkoxy, with the proviso that R 1 and R 2 are not both hydrogen, sufficient to relieve the condition of psoriasis in mammals in combination with a pharmaceutically acceptable, non-toxic carrier suitable for said administration form.
Claim 3
Dependent Claim 11 words
The method according to claim 1 wherein said compound is ##STR11##
Claim 4
Dependent Claim 31 words
The method according to claim 2 wherein R 1 and R 2 are hydroxy and R 3 is selected from the group halo, cyano, and C 1 to C 4 alkoxy.
Claim 5
Dependent Claim 27 words
The method according to claim 2 wherein R 1 is C 1 to C 4 linear or branched alkoxy and R 2 and R 3 are hydrogen.
Claim 6
Dependent Claim 18 words
The method according to claim 3 where R 3 is selected from the group fluoro, chloro and bromo.
Claim 7
Dependent Claim 11 words
The method according to claim 3 wherein R 3 is cyano.
Claim 8
Dependent Claim 14 words
The method according to claim 2 wherein the compound of formula (I) is 2,3-dihydroxy-6-bromo-1,4-naphthoquinone.
Claim 9
Dependent Claim 10 words
The method of claim 1 wherein said compound is 6-chloro-2,3-dihydroxy-1,4-naphthoquinone.

References Cited (Backward Citations)

US3914264A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1983-10-21 1984-04-21 1984-10-21 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1987-10-21 1988-04-21 1988-10-21 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1991-10-21 1992-04-21 1992-10-21 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag